ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,275Medicare Part D Prescriptions Filled, Including Refills

Rank: 133 out of 807

$484K Total Retail Price of All Prescriptions

Rank: 127 out of 807

444 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
24% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Minnesota
Lower avg

Schedule Two
Controlled Substances

2% of this provider’s 444 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

8% of this provider’s 444 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

1% of this provider’s 7,846 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Minnesota
SIMVASTATIN 559 532 1 1
LEVOTHYROXINE SODIUM 337 337 2 3
LISINOPRIL 274 274 3 2
AMLODIPINE BESYLATE 249 239 4 5
METOPROLOL SUCCINATE 218 208 5 13
WARFARIN SODIUM 208 204 6 10
FUROSEMIDE 187 184 7 6
LOSARTAN POTASSIUM 163 161 8 14
POTASSIUM CHLORIDE 159 152 9 18
OMEPRAZOLE 152 146 10 4
ALENDRONATE SODIUM 148 144 11 20
PRAVASTATIN SODIUM 146 145 12 21
ATENOLOL 144 144 13 7
HYDROCHLOROTHIAZIDE 131 120 14 9
ATORVASTATIN CALCIUM 128 121 15 11
METOPROLOL TARTRATE 120 114 16 8
DONEPEZIL HCL 115 115 17 31
LISINOPRIL-HYDROCHLOROTHIAZIDE 113 108 18 28
METFORMIN HCL 106 101 19 12
HYDROCODONE-ACETAMINOPHEN 105 98 S3 20 15
GABAPENTIN 104 96 21 16
CITALOPRAM HBR 98 91 22 17
VENLAFAXINE HCL ER 86 86 23 91
SERTRALINE HCL 83 77 24 22
CRESTOR 79 72 25 32
NAMENDA 73 73 26 54
DIOVAN HCT 72 69 27 166
MELOXICAM 68 68 28 105
ZOLPIDEM TARTRATE 66 63 29 23
TAMSULOSIN HCL 66 53 29 27
DIGOXIN 63 63 31 41
CLONIDINE HCL 62 58 32 82
LANTUS 61 61 33 45
CIPROFLOXACIN HCL 61 55 33 72
TRAMADOL HCL 61 59 33 19
TRAZODONE HCL 60 44 36 25
METFORMIN HCL ER 59 53 37 61
LOSARTAN-HYDROCHLOROTHIAZIDE 58 54 38 55
CLOPIDOGREL 55 50 39 47
RANITIDINE HCL 54 50 40 34
BUPROPION HCL SR 53 49 41 204
PREDNISONE 53 53 41 24
FENOFIBRATE 53 49 41 69
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 1, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.